BLEEDnFIRE Therapeutics launches with non-dilutive funding for first-in-class RNA bleeding-disorder therapy
What's the deal? BLEEDnFIRE Therapeutics (BnF), an early-stage Swiss biotech developing first-in-class RNA therapies for rare bleeding disorders, has officially launched. The company secured non-dilutive funding from InnosuisseDealroom has a profile for this one. Try Dealroom →, Venture KickDealroom has a profile for this one. Try Dealroom →, the Gebert Rüf Foundation Innobooster programme, and KickfundDealroom has a profile for this one. Try Dealroom →.
Why now? The rare bleeding disorder space is attracting growing attention. Recent moves include Hemab Therapeutics setting terms for a $200M IPO and new clinical data showing denecimig significantly reduced bleeding rates in haemophilia A patients. BnF is entering a market where innovation in RNA-based approaches could carve out a distinct niche.
What could go wrong? Non-dilutive funding — grants and awards rather than equity investment — lets founders retain ownership but typically comes in smaller amounts with specific milestones attached. As BnF advances its programmes, it will likely need venture capital or partnerships to fund clinical development, which is expensive and uncertain for rare disease therapies.
First-in-class RNA therapies also face steep regulatory and scientific hurdles. The company must demonstrate both safety and efficacy in small patient populations, where trial recruitment alone can be a major bottleneck.
The signal: BnF's launch reflects two broader trends. First, European biotechs are increasingly leveraging non-dilutive funding to de-risk early-stage work before approaching venture investors. Switzerland's ecosystem — with programmes like Innosuisse and Venture Kick — offers a well-trodden path for this strategy.
Second, RNA therapeutics continue to expand beyond their initial beachheads. After mRNA vaccines and RNA interference drugs proved viable at scale, startups are now targeting smaller, underserved indications where the modality's precision could deliver outsized clinical impact.
Read more: The Pharma Letter
